Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Shorter chemo shows promise for kids with hodgkin lymphoma

NCT ID NCT00846742

Disease control Sponsor: St. Jude Children's Research Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This phase 2 trial is testing a shorter, more intense chemotherapy regimen called Stanford V in children and young adults with favorable Hodgkin lymphoma. Those who still have signs of cancer after 8 weeks of chemo also receive low-dose radiation to the affected areas. The goal is to see if this approach can improve the complete response rate while reducing the need for longer treatment and its side effects. The study enrolled 88 participants aged 21 and younger.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Stanford V chemotherapy (a combination of vinblastine, doxorubicin, vincristine, bleomycin, mechlorethamine, etoposide, and prednisone) with or without low-dose radiation therapy
What this could lead to
If successful, this could offer a shorter, less toxic treatment option for children with favorable Hodgkin lymphoma, potentially reducing long-term side effects while maintaining high cure rates.
What could go wrong
This is a phase 2 trial with only 88 participants, so results are preliminary. The chemotherapy still carries risks like infection, bleeding, and fertility issues, and some children may still need radiation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

88 people

The number who actually took part.

Started

Jun 2009

Expected to finish

Oct 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

Up to 21 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Histologically confirmed, previously untreated Hodgkin lymphoma. * Age: Participants must be 21 years of age or younger * Stage must be classified as one of the following: Ann Arbor stage IA or IIA with: * Non-bulky mediastinal disease (\< 33% mediastinal to thoracic ratio on CXR) * \< 3 nodal regions involved on the same side of the diaphragm * No "E" lesion * Female patients who are post-menarchal must have a negative pregnancy test. Patients of reproductive potential must agree to use an effective contraceptive method. * Signed informed consent * If re-evaluation of a patient's disease shows intermediate risk features, the patient will be removed from the HOD08. Exclusion Criteria: * Intermediate or High risk disease, defined as Stage IB, any III or IV or IA/IIA with "E" lesion(s), 3 or more nodal sites involved, or bulky mediastinal adenopathy

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hodgkin lymphoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Hodgkins lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hodgkin lymphoma

Contacts and locations

Locations

  • Children's Hospital of Illinois at OSF St. Francis Medical Center

    Peoria, Illinois, 61637, United States

  • Dana-Farber Harvard Cancer Center

    Boston, Massachusetts, 02115, United States

  • Maine Children's Cancer Program (MCCP)

    Scarborough, Maine, 04074, United States

  • Packard Children's Hospital, Stanford University

    Palo Alto, California, 94304, United States

  • Rady Children's Hospital- San Diego

    San Diego, California, 92123, United States

  • St. Jude Children's Research Hospital

    Memphis, Tennessee, 38105, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.